Cetuximab administered through pulmonary route in a mice model of lung tumor
2013
Introduction: Emerging evidences indicate that monoclonal antibodies delivered through pulmonary route may be a promising treatment for lung diseases. We assessed the efficacy and tumor distribution of cetuximab, an anti-EGFR antibody, delivered through the pulmonary route in a murine model of lung tumor. Methods: A549-luc cells were orotracheally inoculated into lungs of Balb/C nude females to develop an orthotopic murine model of NSCLC sensitive to cetuximab. Nine days after inoculation, tumor were treated with cetuximab intraperitoneally (n=15), aerosol cetuximab (n=17) at a dose of 10 mg/kg or NaCl aerosol (n=16), once a week for three weeks. Bioluminescence imaging was used to homogenise group before treatment and to follow up tumor growth. For intratumoral biodistribution study, cetuximab was conjugated to a fluorophore and delivered in the orthotopic mouse model of NSCLC either through ip, iv or the pulmonary route. Three dimensional near-infrared fluorescence imaging (NIRF) was used to determine tumor uptake of cetuximab. Results: As shown by bioluminescence imaging, the growth of A549-luc tumors was statistically decreased by 40% in mice treated with aerosolized cetuximab and 24% in the group treated with ip cetuximab comparatively to the control group (p Conclusion: The pulmonary delivery of mAb, such as cetuximab, may be relevant for treating respiratory diseases, but further investigations are required to understand the molecular mechanisms associated with the therapeutic response.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI